Normalized T2-signal intensity (nT2SI) and SI on diffusion-weighted imaging (b=1000 and 2000 mm2/s), apparent diffusion coefficient (ADC) values, peak SI, SI at the end of the dynamic curves, mean peak time, mean enhancement percentage, and washout percentage obtained from dynamic contrast-enhanced imaging (DCEI) were measured.Results: nT2SI (3.8 vs. 3.2, p=0.003) and ADC values (0.685×10−3 mm2/s vs. 0.874×10−3 mm2/s, p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:mpMRI) in differentiating prostate cancer (PCa) from prostatitis foci.Materials and Methods: This retrospective analysis included 81 biopsy-proven lesions (44 prostatitis and 37 PCa).
📊
Key Findings & Data:mpMRI) in differentiating prostate cancer (PCa) from prostatitis foci.Materials and Methods: This retrospective analysis included 81 biopsy-proven lesions (44 prostatitis and 37 PCa).
💡
Conclusion & Impact:Normalized T2-signal intensity (nT2SI) and SI on diffusion-weighted imaging (b=1000 and 2000 mm2/s), apparent diffusion coefficient (ADC) values, peak SI, SI at the end of the dynamic curves, mean peak time, mean enhancement percentage, and washout percentage obtained from dynamic contrast-enhanced imaging (DCEI) were measured.Results: nT2SI (3.8 vs. 3.2, p=0.003) and ADC values (0.685×10−3 mm2/s vs. 0.874×10−3 mm2/s, p
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters
Abstract
mpMRI) in differentiating prostate cancer (PCa) from prostatitis foci.Materials and Methods: This retrospective analysis included 81 biopsy-proven lesions (44 prostatitis and 37 PCa). Normalized T2-signal intensity (nT2SI) and SI on diffusion-weighted imaging (b=1000 and 2000 mm2/s), apparent diffusion coefficient (ADC) values, peak SI, SI at the end of the dynamic curves, mean peak time, mean enhancement percentage, and washout percentage obtained from dynamic contrast-enhanced imaging (DCEI) were measured.Results: nT2SI (3.8 vs. 3.2, p=0.003) and ADC values (0.685×10−3 mm2/s vs. 0.874×10−3 mm2/s, p
🔖
Cite This Article
ERDEN, A., PEKER, E., SÖNMEZ, D. Y., AKKAYA, H. E., HAYME, S., ERDEN, M. İ. (2022). Diagnostic Performance of Multiparametric MR Imaging at 3.0 Tesla in Discriminating Prostate Cancer from Prostatitis: A Histopathologic Correlation. Eurasian Journal of Medicine, Cilt: 51 - Sayı: 1, 31–37. https://ajindex.com/articles/508958
Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31: 85-90. [CrossRef] 2. Sah VK, Wang L, Min X, et al. Multiparametric MR imaging in diagnosis of chronic prostatitis and its differentiation from prostate cancer. Radiol Infectious Diseases. 2015; 1: 70-77. [CrossRef] 3. Nagel KN, Schouten MG, Hambrock T, et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 2013; 267: 164-72. [CrossRef] 4. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics 2011; 31: 677-703. [CrossRef] 5. Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A. Benign conditions that mimic prostate carcinoma: MR imaging features with histopathologic correlation. Radiographics 2016; 36: 162-175. [CrossRef] 6. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-334. [CrossRef] 7. Esen M, Onur MR, Akpolat N, Orhan I, Kocakoc E. Utility of ADC measurement on diffusion-weighted MRI in differentiation of prostate cancer, normal prostate and prostatitis. Quant Imaging Med Surg 2013; 3: 210-215. 8. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292: 2735-2742. [CrossRef] 9. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging-Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69: 16-40. [CrossRef] 10. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723. [CrossRef] 11. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55: 99-109. [CrossRef] 12. Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate 1995; 26: 111-115. [CrossRef]